Radiofrequency Ablation: A Promising Treatment Method for Abdominal Wall Endometriosis
CardioVascular and Interventional Radiology · 2024
DOI: 10.1007/s00270-024-03755-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift CardioVascular and Interventional Radiology, 2024. Verfasst von Ali Mahdavi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Endometriosis, Abdominal Wall, Ultrasonography, Interventional, Pain Measurement. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Academic Center for Education, Culture and Research.
Abstract (Originalsprache)
PURPOSE: To evaluate the application of radiofrequency ablation (RFA) as a treatment method for abdominal wall endometriosis (AWE). MATERIALS AND METHODS: The characteristics of the AWE lesions in the patients were obtained using ultrasound (US). The patients received general and local anesthesia, and then, AWE lesions were divided into 1 cm3 sections visually, and each of these sections underwent US-guided RFA using the moving shot technique. Follow-up included outpatient appointments, including a US examination 1, 3, and 6 months after the treatment to assess the volume of the lesions. In addition, the level of pain experienced by the patients was measured using a visual analogue scale (VAS) before and the day after the procedure, as well as at each follow-up appointment. RESULTS: Ten patients were treated with RFA. The procedural success was achieved in all of the patients. The median volume of the lesions decreased from 7.3 cm3 (IQR = 4.39,23.75) to 2.95 cm3 (IQR = 1.65,9.09) (P = 0.005). All patients reported reduced pain levels, and the median of their VAS score decreased from 9 (IQR = 8,9) to 0 (IQR = 0,1.25) (P = 0.004) at the end of the follow-up period. None of the patients experienced complications related to RFA treatment. CONCLUSION: Based on the study's findings, RFA appears to be a promising minimally invasive treatment for AWE. However, larger studies with longer follow-up periods are required for a more comprehensive understanding of its efficacy and safety. LEVEL OF EVIDENCE: Level 4, Case Series.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. s.ali.forouzannia@gmail.com.
- Department of Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Medicine, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
- Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.
- Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Förderung
- Academic Center for Education, Culture and Research
Zitieren
APA
Mahdavi, A., Forouzannia, S. A., Goudarzi, E., Forouzannia, S. M., Rafiei, R., Yousefimoghaddam, F., Rafiei, N., & Padmehr, R. (2024). Radiofrequency Ablation: A Promising Treatment Method for Abdominal Wall Endometriosis. CardioVascular and Interventional Radiology. https://doi.org/10.1007/s00270-024-03755-4
Vancouver
Mahdavi A, Forouzannia SA, Goudarzi E, Forouzannia SM, Rafiei R, Yousefimoghaddam F, et al. Radiofrequency Ablation: A Promising Treatment Method for Abdominal Wall Endometriosis. CardioVascular and Interventional Radiology. 2024. doi:10.1007/s00270-024-03755-4
BibTeX
@article{Mahdavi2024,
author = {Mahdavi, Ali and Forouzannia, Seyed Ali and Goudarzi, Ehsan and Forouzannia, Seyed Mohammad and Rafiei, Romina and Yousefimoghaddam, Fateme and Rafiei, Niloufar and Padmehr, Roya},
title = {Radiofrequency Ablation: A Promising Treatment Method for Abdominal Wall Endometriosis},
journal = {CardioVascular and Interventional Radiology},
year = {2024},
doi = {10.1007/s00270-024-03755-4}
}
EUVIMED